Page 14 - அல்லாத சிறிய செல் நுரையீரல் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Twice as many patients with advanced lung cancer carrying high PD-L1 expression lived 5 years or longer if they started treatment with pembrolizumab (Keytruda) instead of chemotherapy, long-term follow-up from a randomized trial showed. Five-year overall survival (OS) was 31.9% in pembrolizumab-treated patients and 16.3% for patients who received chemotherapy. Median OS also was twice as long with pembrolizumab, 26.3 months versus 13.4 months (HR 0.62, 95% CI 0.48-0.81). The advantage for treatment with the PD-1 inhibitor emerged despite the fact that two-thirds of patients in the chemotherapy group eventually crossed over to the immunotherapy arm, which might have led to underestimation of the magnitude of benefit with pembrolizumab, investigators reported in the

Schleswig holsteinMartin reckCharles bankheadLung center grosshansdorfMedpage todayLung cancerNon small cell lung cancerஸ்சிலேசுவிக் ஹோல்ஸ்டீன்மார்டின் ரெக்சார்லஸ் வங்கித் தலைநுரையீரல் புற்றுநோய்அல்லாத சிறிய செல் நுரையீரல் புற்றுநோய்